Arcutis Biotherapeutics, Inc.

NasdaqGS:ARQT Stock Report

Market Cap: US$1.0b

Arcutis Biotherapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:ARQT Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
02 Oct 24SellUS$37,295Larry EdwardsIndividual3,725US$10.01
24 Sep 24SellUS$110,264David TopperIndividual11,626US$9.48
03 Sep 24SellUS$107,695Howard WelgusIndividual10,000US$10.77
19 Aug 24SellUS$14,318Patrick BurnettIndividual1,728US$8.29
02 Aug 24SellUS$130,648Todd WatanabeIndividual14,487US$9.02
29 May 24SellUS$435,387Patrick BurnettIndividual49,952US$8.72
28 May 24SellUS$15,988Masaru MatsudaIndividual1,775US$9.01
17 May 24SellUS$68,582Larry EdwardsIndividual7,640US$8.98
02 May 24SellUS$40,902Matthew MooreIndividual4,681US$8.74
04 Mar 24BuyUS$199,994Frazier Life Sciences Management, LPCompany21,052US$9.50
04 Mar 24SellUS$38,568Matthew MooreIndividual3,468US$11.12
04 Mar 24BuyUS$199,994Frazier Life Sciences Management, LPCompany21,052US$9.50
02 Jan 24SellUS$4,692Patrick BurnettIndividual1,325US$3.54
01 Dec 23BuyUS$9,334Todd WatanabeIndividual1,463US$6.38
21 Nov 23SellUS$3,661Masaru MatsudaIndividual1,850US$1.98

Insider Trading Volume

Insider Buying: ARQT insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of ARQT?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders2,414,2631.83%
VC/PE Firms8,785,2846.66%
Hedge Funds19,821,16415%
Institutions100,895,43176.5%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 23.8%.

Top Shareholders

Top 25 shareholders own 89.51% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
9.9%
Jennison Associates LLC
11,571,694US$100.3m-4.97%0.06%
8.56%
Suvretta Capital Management, LLC
10,004,492US$86.7m27%3.03%
8.4%
Rubric Capital Management LP
9,816,672US$85.1m30.7%1.3%
7.72%
BlackRock, Inc.
9,029,624US$78.3m4.72%no data
7.52%
Frazier Life Sciences Management, LP
8,785,284US$76.2m0%3.06%
5.89%
Polar Capital Holdings Plc
6,879,072US$59.6m-0.1%0.22%
5.26%
The Vanguard Group, Inc.
6,144,290US$53.3m18.9%no data
4.39%
State Street Global Advisors, Inc.
5,134,843US$44.5m-41.5%no data
3.8%
Franklin Resources, Inc.
4,437,939US$38.5m-4.4%0.01%
3.37%
Morgan Stanley, Investment Banking and Brokerage Investments
3,939,271US$34.2m-0.59%no data
3.09%
Gilder Gagnon Howe & Co. LLC
3,616,532US$31.4m-14.6%0.35%
2.51%
Citadel Advisors LLC
2,932,647US$25.4m53.2%0.02%
2.16%
Cormorant Asset Management, LP
2,525,000US$21.9m18.8%0.96%
2.07%
Geode Capital Management, LLC
2,421,270US$21.0m22.8%no data
1.83%
Ensign Peak Advisors, Inc.
2,133,702US$18.5m-28.4%0.03%
1.75%
Pivotal BioVenture Partners LLC
2,041,108US$17.7m0.65%6.3%
1.61%
Deutsche Asset & Wealth Management
1,882,025US$16.3m0.5%no data
1.52%
Medical Strategy GmbH, Asset Management Arm
1,779,301US$15.4m358%0.86%
1.43%
GW&K Investment Management, LLC
1,667,979US$14.5m-3.1%0.12%
1.33%
Perceptive Advisors LLC
1,558,500US$13.5m108%0.27%
1.15%
Tejara Capital Limited., Asset Management Arm
1,343,609US$11.6m42.9%4.18%
1.12%
J. Goldman & Co., L.P.
1,311,549US$11.4m-8.62%0.38%
1.12%
Candriam
1,307,481US$11.3m0%0.03%
1.05%
American Century Investment Management Inc
1,231,700US$10.7m18.3%0.01%
0.97%
JP Morgan Asset Management
1,136,876US$9.9m28.9%no data